



# Sprint Bioscience

## **Investor presentation**

Johan Emilsson, Chief Executive Officer  
March 2026

# Sprint Bioscience in brief

An innovative pharmaceutical company developing drug programs in preclinical phase for the treatment of cancer

## ● VISION

*To extend and improve the lives of cancer patients as a sustainable profitable growth company*




# Company overview



- Founded 2009 - IPO 2014
- Drug development programs targeting:
- Oncology:
  - immuno-oncology
  - tumor metabolism
  - tumor microenvironment
- Drug development using Fragment-based Drug Design (FBDD)
- Located in Stockholm County, Sweden

# What we do – core competences

Comprehensive inhouse development capabilities



Protein Science

Structural Biology

Computational  
Chemistry


Medicinal  
Chemistry

Cell Biology




# How its done


Tailor-made molecule designed to fit the protein pocket and block its function



Target protein



Biological molecule



Sprint Bioscience's  
molecule

# Fragment-based drug design (FBDD)


FBDD is a proven approach

**FBDD has played a central role in discovering seven FDA approved drugs, and another 50 fragment-derived compounds are currently in clinical development**


Drug	Mechanism	Indication	Approval	Company
Capivasertib	AKT	Breast cancer	2023	AstraZeneca
Asciminib	Allosteric BCR-ABL	CML	2021	Novartis
Sotorasib	Kras	NSCLC	2021	Amgen
Pexidartinib	CSF1R	Tenosynovial giant cell tumor	2019	Daiichi Sankyo
Erdafitinib	Tyrosine kinase inhibitor	Bladder cancer	2019	J&J
Venetoclax	BCL-2 inhibitor	Leukemia	2016	AbbVie
Vemurafenib	BRAF kinase inhibitor	Advanced melanoma	2011	Roche

# Market insights - discovery stage deal making

## Breakdown of deals by development stage



## Therapeutic area



Source: Adapted from William Blair, *The Quarterly Rx: Q3 2025 U.S. Biopharma Recap*.

# Historic deal – validates science


● PRESS RELEASE

## Sprint Bioscience sells the TREX1 program to Gilead

24 nov. 2025 06:08:00

Regulatorisk


Sprint Bioscience AB (publ) today announces the sale of its TREX1 cancer program to Gilead Sciences, Inc. The agreement includes an upfront payment of USD 14 million, as well as potential clinical, regulatory, and commercial milestone payments totaling up to USD 400 million.



Sprint  
Bioscience




# Biotech deal data in Sweden




Source: Redeye Nordic Growth Research update 2025-12-04. Biotech deals (according to Redeye's assessment); pharma deals and certain merger or collaboration agreements are not included

# Core business and revenue model



# Business model



# DCPS & VRK1

Synthetic lethality programs


## ● DCPS

- **New mode-of-action**
- Strong literature rationale for targeting **Acute Myeloid Leukaemia**
  - DCPS is essential for AML cell survival
  - DCPS inhibition does not affect normal haematopoiesis
- Target proven to be **safe in the clinic**

## ● VRK1

- **Novel target** in VRK2-low **Glioblastoma**
- Addressing several aspects of tumor biology:
  - DNA-damage response
  - Cell cycle control
  - STING-dependent immune signaling
- **In vivo efficacy** verified in tumor-bearing animals

# Pipeline



## Patents

Sprint Bioscience strategically positions its IP to optimize patent timing. This approach extends market exclusivity and maintains flexibility. With expertise in patent strategy and data readiness, drug candidates remain attractive to partners that may want to take part in forming an optimized IP positioning.



# Sprint Bioscience as an investment

Proven Business model with unique platform

Attractive and diversified portfolio with scalability

Strong pipeline of programs

Existing and new potential partnerships



Sprint  
Bioscience

# Sprint Bioscience



Contact: Johan Emilsson, CEO  
[johan.emilsson@sprintbioscience.com](mailto:johan.emilsson@sprintbioscience.com)

[www.sprintbioscience.com](http://www.sprintbioscience.com)